AI assistant
ImmunityBio, Inc. — Director's Dealing 2026
Jan 5, 2026
31529_dirs_2026-01-05_7dc6b0ad-e945-420b-88c2-05c2372eafdf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2025-12-31
Reporting Person: Adcock Richard (Director, CEO & President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Common Stock | M | 34483 | — | Acquired | 368901 | Direct |
| 2025-12-31 | Common Stock | F | 17510 | $1.98 | Disposed | 351391 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Restricted Stock Units | $ | M | 34483 | Disposed | Common Stock (34483) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2: On December 31, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 30, 2025 was the settlement price used to calculate the shares withheld.
F3: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.